OCT Clinical, a leading CRO from Eastern Europe, teamed up with UK-based Futura Medical to conduct the FM71 study. This study evaluated the innovative MED3000 topical gel for the treatment of erectile dysfunction (ED). The confirmatory trial successfully enrolled 100 male participants with diverse demographics across four countries – Poland, Georgia, the USA, and Bulgaria. Efficiently completed and ahead of schedule, the study marks a significant advancement in ED treatment options. It showcases how a CRO’s expertise in managing complex, multi-national clinical trials can contribute to the success of a study.
Download the full text to learn more about the outcomes of this study.
